tradmap

BBNX Beta Bionics, Inc.

$15.90 -4.96%

Data as of close

Healthcare · Surgical & Medical Instruments & Apparatus

Beta Bionics, Inc. (BBNX) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $864 million. Shares last traded at $15.90, 52.5% below their 52-week high. Over the past year the stock is down 40.6%. Net profit margin is -65.3%, below the peer median of -6.9%. Revenue grew 53.9% year over year.

Market Cap
$864M
Shares Out
54.4M
EPS (TTM)
-$1.70
P/E (TTM)*
—
P/S Ratio
6.79
P/B Ratio
2.15
Dividend / Share
—
Dividend Yield
—
52-Week High
$33.50
52-Week Low
$8.80
Volume (venue)
60,438
Avg Vol (3m, venue)
72,107.905

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-22.46%
1M
-16.12%
3M
+9.50%
6M
+55.88%
YTD
-47.82%
1Y
-40.58%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
37.55
SMA (50)
$18.99
SMA (200)
$14.80
Price vs SMA50
-16.27%
Price vs SMA200
+7.46%
ATR (14)
$1.43

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$127M
Net Income
-$83M
Gross Margin
58.6%
Operating Margin
-72.7%
Net Margin
-65.3%
Return on Equity
-20.7%
Return on Assets
-18.7%
Current Ratio
8.92
Debt / Equity
0.11
Revenue Growth (YoY)
+53.9%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 -$0.52 2026-10-27
Q2 2026 -$0.53 2026-07-29
Q1 2026 -$0.49 2026-04-21
Q4 2025 (derived) -$0.16 2026-02-24
FY 2025 -$1.81 2026-02-24
Q3 2025 -$0.33 2025-10-28

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Surgical & Medical Instruments & Apparatus peers

BBNX vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close

P/S vs peers
6.79 / 2.81 med
+142% premium
Net margin vs peers
-65.3% / -6.9% med
below median
1–14 of 14
SYKStryker Corporation$116.8B32.254.4413.8%+5.32%
MMM3M$92.2B26.073.6514.0%+2.35%
BSXBoston Scientific$64.3B18.393.0516.6%+5.62%
BDXBecton Dickinson$54.1B57.492.604.5%+0.39%
RMDResMed$32.8B20.565.7127.8%+1.35%
DXCMDexCom$31.6B31.906.1919.4%+2.99%
MDLNMedline Inc.$29.5B—1.04—+4.80%
WSTWest Pharmaceutical Services$28.4B44.468.3618.8%-1.15%
SOLVSolventum$14.4B10.061.7417.3%+4.22%
GKOSGlaukos Corp$14.1B—20.48-24.6%+0.53%
PENPenumbra Inc$12.7B80.679.0211.2%+0.42%
BAXBaxter International$12.5B—1.08-6.2%+5.47%
GMEDGlobus Medical Inc$10.7B19.923.3917.0%+1.81%
PODDInsulet Corporation$10.7B28.393.4912.3%+2.58%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.